Clinical Trials Directory

Trials / Completed

CompletedNCT04401137

The Evaluation of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of QDX in Healthy Korean Male Subjects

A Single Center, Randomized, Double Blind, Placebo Controlled, Dose Escalation Clinical Trial to Evaluate Pharmacokinetic/Pharmacodynamic Characteristics and Safety of QDX After Single Oral Administration in Healthy Korean Male Subjects

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
42 (actual)
Sponsor
SK Chemicals Co., Ltd. · Industry
Sex
Male
Age
19 Years – 45 Years
Healthy volunteers
Accepted

Summary

To evaluate pharmacokinetic/pharmacodynamic characteristics and safety of QDX after single oral administration in healthy Korean male subjects

Conditions

Interventions

TypeNameDescription
DRUGTopiramateTopiramate

Timeline

Start date
2020-07-01
Primary completion
2020-10-06
Completion
2020-10-06
First posted
2020-05-26
Last updated
2020-10-27

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT04401137. Inclusion in this directory is not an endorsement.